Targeted drug plus chemotherapy for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding a targeted drug (fruquintinib) to standard chemotherapy works better than chemotherapy alone as the first treatment for advanced or recurrent endometrial cancer that is pMMR. It may help control the cancer for a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced, recurrent, or have spread, and it must be the type called 'pMMR' (meaning your tumor has normal repair proteins).
- You should not have had any prior chemotherapy or targeted therapy for advanced disease. If your cancer came back more than 6 months after completing adjuvant therapy (therapy given after surgery), you may still qualify.
- You need to be in generally good health, with a performance status of 0 or 1 (able to carry out daily activities).
- Your kidney, liver, and blood counts must be within acceptable limits.
- You must be willing to use effective birth control during and for a few months after the study if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
This study tests a new treatment for advanced or metastatic esophageal cancer that has not responded to previous chemotherapy. It aims to see if this treatment can help slow down the cancer or shrink tumors.
This trial tests a combination of two drugs – fruquintinib (a pill that targets blood vessels feeding tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer) – for people with advanced endometrial cancer that has already been treated with platinum chemotherapy. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a new medicine called QL1706 (a type of immunotherapy that helps your immune system fight cancer) combined with chemotherapy for women with advanced or recurrent endometrial cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.